中文摘要

Morinda citrifolia為天然植物，已被證實有抗癌特性，但無文獻指出Morinda citrifolia中的有效抗癌成分組成。因此，本研究是利用不同溶劑萃取Morinda citrifolia，利用高效液相層析法（ HPLC ； High Performance. Liquid Chromatography ）分析Morinda citrifolia萃取物中有效抗癌成分，進一步將有效抗癌成份與臨床藥物Rapamycin結合測試是否具有協同作用可抑制乳癌細胞生成。Morinda citrifolia以甲醇、氯仿、乙醇、水-乙酸乙酯和乙酸乙酯等五種萃取萃取，得知水-乙酸乙酯萃取法的各個Polyphenol含量較為高，其中有效抗癌成份為Chrysin類似物，並且水-乙酸乙酯粗萃取物可抑制MCF-7和MDA-MB-231乳癌細胞生長。接續，以Chrysin、Apigenin、Rapamycin併用發現可協同抑制MCF-7和MDA-MB-231乳癌細胞生長，進而促使乳癌細胞凋亡現象。另外，以MDA-MB-231乳癌細胞植入裸鼠大腿皮下，每日以Chrysin、Rapamycin併用腹腔注射治療裸鼠，25天後發現Chrysin、Rapamycin併用可抑制腫瘤生長，並可抑制腫瘤中Ki-67的蛋白表現。因此，Chrysin、Apigenin、Rapamycin併用有成為治療乳癌藥物的潛力，值得進一步探討其作用機制。

Abstract

Morinda citrifolia (Noni), a natural plant product, has been shown to have anti-cancer properties. However, the chemical components of Morinda citrifolia still have not been extensively studied. Therefore, the major purpose of this study was to evaluate the biological potential of Morinda citrifolia. This study would establish the composition of Morinda citrifolia by High Performance Liquid Chromatography (HPLC) assay, and furthermore evaluate the anti-cancer effects of Morinda citrifolia extract in MCF-7 and MDA-MB-231 breast cancer cells. The Morinda citrifolia fruits extracts were extracted with ethanol, methanol, chloroform, ethyl acetate, water- ethyl acetate. The water-ethyl acetate extract from Morinda citrifolia fruits have the highest anticancer activity against MCF-7 and MDA-MB-231 breast cancer cells. The HPLC data show that chrysin analog were predominantly present in the Water-EtOAc extracts of Morinda Citrifolia fruit. Furthermore, the combination effects of rapamycin and flavonoids (chrysin and apigenin) were evaluated using MTT data, flow cytometry and Hoechst 33258 Dye assay. MTT assay indicated that rapamycin combined with flavonoids (chrysin and apigenin) synergistically reduced MCF-7 and MDA-MB-231 cancer cells viability, and induced apoptosis. Additionally, rapamycin combined with chrysin also suppressed tumor growth in nude mice with xenografted MDA-MB-231 cancer cells through the down-regulation of ki-67 protein. Thus, the combination of rapamycin and flavonoids (chrysin and apigenin) warrants further study as a potential in breast cancer treatment.

1. 天下雜誌健康醫療(http://www.cw.com.tw/article/article.action?id=5049130)
2. Yip CH.2009.Breast cancer in Asia. Methods Mol Bio,471:51-64.
3. 乳癌防治基金會
4. 三軍總醫院
5. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C.2009. A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cance. Cancer Res,69(13):5364-73.
6. Chen J, Han Q, Pei D.2012. EMT and MET as paradigms for cell fate switching. J Mol Cell Biol,4(2):66-9.
7. VandenBussche CJ, Elwood H, Cimino-Mathews A, Bittar Z, Illei PB, Warzecha HN.2013. Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype. Hum Pathol,44(11):2487-93.
8. Mieke Schutte, Ralph H. Hruban, Joseph Geradts, Rob Maynard, Werner Hilgers, Sridhar K. Rabindran,Christopher A. Moskaluk, Stephan A. Hahn, Irmgard Schwarte-Waldhoff, Wolff Schmiegel, Stephen B. Baylin,Scott E. Kern, and James G. Herman.1997. Abrogation of the Rb/p16 Tumor-suppressive Pathway in Virtually AllPancreatic Carcinomas. CANCERRESEARCH,57:3126-313.
9. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL.2008. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol.,216(2):141-50.
10. Christos Sotiriou, Soek-Ying Neo, Lisa M. McShane, Edward L. Korn, Philip M. Long, Amir Jazaeri, Philippe Martiat, Steve B. Fox, Adrian L. Harris, and Edison T. Liu.2003.Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Christos Sotiriou,10393–10398.
11. 中華民國乳癌病友協會
12. Rakesh Kumar Gupta, Deepti Bajpai, Neeta Singh.Influence of Morinda citrifolia (Noni) on Expression of DNA Repair Genes in Cervical Cancer Cells.2015 Asian Pac J Cancer Prev, 16 (8), 3457-3461.
13. Caramel S, Marchionni M, Stagnaro S.2015. Morinda citrifolia Plays a Central Role in the Primary Prevention of Mitochondrial-dependent Degenerative Disorders. Asian Pac J Cancer Prev,16(4):1675.
14. Barani Kumarasamy, Sunayana Manipal, Prabu Duraisamy, Adil Ahmed, Mohanaganesh SP, Jeevika C.2014.Role of aqueous extract of morinda citrifolia (Indian noni) ripe fruits in inhibiting dental caries-causing streptococcus mutans and streptococcus mitis. Journal of dentistry (Tehran, Iran) ,11(6):703-10.
15. Aziz MY, Omar AR, Subramani T, Yeap SK, Ho WY, Ismail NH, Ahmad S, Alitheen NB. 2014.Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-7 breast cancer cells. Oncol Lett,7(5):1479-1484.
16. Amit Kumar Patel,Neeta Singh.2013. Morinda citrifolia (Noni) Alters Oxidative Stress Marker and Antioxidant Activity in Cervical Cancer Cell Lines. Asian Pacific journal of cancer prevention,14(8):4603-4606.
17. Gupta RK, Banerjee A, Pathak S, Sharma C, Singh N. 2013.Induction of Mitochondrial-Mediated Apoptosis by Morinda Citrifolia (Noni) in Human Cervical Cancer Cells. Asian Pac J Cancer Prev,14(1):237-42.
18. Marijana Kosanić,Branislav Rankovic,Branislav Rankovic,Tatjana P Stanojkovic.2014.Biological activities of two macroalgae from Adriatic coast of Montenegro. Saudi Journal of Biological Sciences,22(4).
19. Turati F, Rossi M, Pelucchi C, Levi F, La Vecchia C.2015.Fruit and vegetables and cancer risk: a review of southern European studies. Br J Nutr,2:S102-10.
20. Elham Anari, Abolfazl Akbarzadeh, and Nosratollah Zarghami.2015.Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line. doi:10.3109/21691401.
21. Ha SK, Moon E, Kim SY.2010.Chrysin suppresses LPS-stimulated proinflammatory responses by blocking NF-κB and JNK activations in microglia cells. Neurosci Lett,485(3):143-7.
22. Eshvendar Reddy Kasala,Lakshmi Narendra Bodduluru, Chandana C. Barua, Ranadeep Gogoic.2015.Chrysin and its emerging role in cancer drug resistance. Chemico-Biological Interactions ,236:7–8.
23. Xia Y, Lian S, Khoi PN, Yoon HJ, Joo YE, Chay KO, Kim KK, Do Jung Y.2015.Chrysin inhibits tumor promoter-induced MMP-9 expression by blocking AP-1 via suppression of ERK and JNK pathways in gastric cancer cells. PLoS One,10(4):e0124007.
24. Benford Mafuvadze,Indira Benakanakere,Franklin R. Lopez Perez,Cynthia Besch-Williford,Mark R Ellersieck,Salman M Hyder.2011.Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague–Dawley Rats. Cancer Prevention Research,4(8):1316-24.
25. Sung Min Ju, Jun Gue Kang, Jun Sang Bae, Hyun Ock Pae, Yeoung Su Lyu, and Byung Hun Jeon.2015.The Flavonoid Apigenin Ameliorates Cisplatin-Induced Nephrotoxicity through Reduction of p53 Activation and Promotion of PI3K/Akt Pathway in Human Renal Proximal Tubular Epithelial Cells. Evid Based Complement Alternat Med,doi: 10.1155/2015/186436.
26. Aitor Andueza, Antonia García-Garzón, Marina,Ruiz de Galarreta, Eduardo Ansorena, María J.,Iraburu, María J. López-Zabalza, Juan J. MartínezIrujo.2015. Oxidation pathways underlying the pro-oxidant effects of apigenin. Free Radical Biology and Medicine,S0891-5849(15)00271-3.
27. Pei-Shan Wu, Jui-Hung Yen, Mei-Chun Kou, Ming-Jiuan Wu.2015.Luteolin and Apigenin Attenuate 4-Hydroxy-2-Nonenal-Mediated Cell Death through Modulation of UPR, Nrf2-ARE and MAPK Pathways in PC12 Cells. PLoS ONE 10(6): e0130599.
28. Seo HS, Sikder MA, Lee HJ, Ryu J, Lee CJ.2014.Apigenin Inhibits Tumor Necrosis Factor-a-Induced Production and Gene Expression of Mucin through Regulating Nuclear Factor-Kappa B Signaling Pathway in Airway Epithelial Cells. Biomol Ther (Seoul),22(6):525-31.
29. Way TD, Kao MC, Lin JK.2004.Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neu in HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway. J Biol Chem,279(6):4479-89.
30. Jundt F, Raetzel N, Müller C, Calkhoven CF, Kley K, Mathas S, Lietz A, Leutz A, Dörken B.2005.A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood, 106(5):1801-7.
31. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F. 2004.Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clin Cancer Res,10(3):1013-23.
32. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. 2004.Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells. Clin Cancer Res. ,10(20):7031-42.
33. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R.2005.Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol, 46(4):481-6.
34. Nourse J1, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM.1994.lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature,372(6506):570-3.
35. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA.2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature,460(7253):392-5.
36. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F.2004. Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clin Cancer Res,10(3):1013-23.
37. Chen Y, Zheng Y, Foster DA.2003.Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene,22(25):3937-42.
38. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE.2007. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med,357(26):2666-76.
39. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L.2003. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. J Clin Oncol. 21(6):976-83.
40. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.2005. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 97(22):1652-62.
41. Early Breast Cancer Trialists' Collaborative Group.2001.Tamoxifen for early breast cancer: an overview of the randomised trials. Cochrane Database Syst Rev, (1):CD000486.
42. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L.2003.Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. J Clin Oncol,21(6):976-83.
43. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE.1999. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. J Clin Oncol,17(2):460-9.
44. Arpornsuwan T, Punjanon T. 2006.Tumor cell-selective antiproliferative effect of the extract from Morinda citrifolia fruits. Phytother Res,20(6):515-7.
45. Thitiporn Anekpankul, Motonobu Goto, Mitsuru Sasaki, Prasert Pavasant, Artiwan Shotipruk.2007. Extraction of anti-cancer damnacanthal from roots of Morinda citrifolia by subcritical water. Separation and Purification Technology,55(3):343-349.
46. Wang MY, Su C.2001.Cancer Preventive Effect of Morinda citrifolia (Noni). Ann N Y Acad Sci,952:161-8.
47. Z.Mohd Zin, A Abdul-Hamid, A Osman.2002. Antioxidative activity of extracts from Mengkudu (Morinda citrifolia L.) root, fruit and leaf. Food Chemistry,78(2):227-231.
48. Yang B, Huang J, Xiang T, Yin X, Luo X, Huang J, Luo F, Li H, Li H, Ren G.2014.Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. J Appl Toxicol,34(1):105-12.
49. Premratanachai P1, Chanchao C.2014.Review of the anticancer activities of bee products. Asian Pac J Trop Biomed,4(5):337-44.
50. Samarghandian S, Afshari JT, Davoodi S.2011.Chrysin reduces proliferation and induces apoptosis in the human prostate cancer cell line pc-3. Clinics (Sao Paulo), 66(6):1073-9.
51. S Leena Sankari,KMK Masthan, N Aravindha Babu,Tathagata Bhattacharjee,M ElumalaiApoptosis in cancer--an update. 2012.Apoptosis in cancer. Asian Pacific J Cancer Prev, 13 (10), 4873-4878.
52. Sean P Cregan1, Valina L Dawson and Ruth S Slack.2004.Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene,23: 2785–2796.
53. Reiner U. Jänicke.2009.MCF-7 breast carcinoma cells do not express caspase-3.Breast Cancer Research and Treatment,117(1):219-221.
54. Eulalia Pozo-Guisado1, Jaime M. Merino1, Sonia Mulero-Navarro1, M. Jesús Lorenzo-Benayas2, Francisco Centeno2, Alberto Alvarez-Barrientos3 andPedro M.Fernandez Salguer.2005. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-Κb. International Journal of Cancer,115(1):74-84.
55. Urruticoechea A, Smith IE, Dowsett M.2005. Proliferation Marker Ki-67 in Early Breast Cancer. J Clin Oncol,23(28):7212-20.
56. Cirqueira MB, Moreira MA, Soares LR, Cysneiros MP, Vilela MT, Freitas-Junior R.2015.Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma. Breast J, doi: 10.1111/tbj.12441.
57. Li T, Zhang C, Ding Y, Zhai W, Liu K, Bu F, Tu T, Sun L, Zhu W, Zhou F, Qi W, Hu J, Chen H, Sun X.2015.Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway. Oncol Rep, doi: 10.3892/or.2015.4109.
58. Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, von Ahsen O.2012. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer,12:178.
59. Chie Kudo-Saitocorrespondenceemail, Hiromi Shirako, Tadashi Takeuchi, Yutaka Kawakami.2009.Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells.Cancer cell,15(3):195-206.
60. Satelli A, Li S.2011. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci,68(18):3033-46.
61. Walid A. Osta , Yian Chen , Kaidi Mikhitarian , Michael Mitas , Mohamed Salem , Yusuf A. Hannun , David J. Cole , and William E. Gillanders.2004. EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy. Cancer Res ,64:5818.
62. David Olmeda, Gema Moreno-Bueno, Juana M. Flores, Angels Fabra, Francisco Portillo, and Amparo Cano.2007. SNAI1 Is Required for Tumor Growth and Lymph Node Metastasis of Human Breast Carcinoma MDA-MB-231 Cells. Cancer Res,67: 11721.
63. Anne Hirazumi and Eiichi Furusawa .1999.An Immunomodulatory Polysaccharide-Rich Substance from the Fruit Juice of Morinda citrifolia (Noni) with Antitumour Activity. Phytother. Res. 13, 380–387.
64. M.Y. WANG AND C. SU.2001.Cancer Preventive Effect of Morinda citrifolia (Noni). Ann N Y Acad Sci,952:161-8.
65. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N.2007.Metformin Inhibits Mammalian Target of Rapamycin–Dependent Translation Initiation in Breast Cancer Cells. Cancer Res,67(22):10804-12.
66. 台灣癌症防治網
67. Heather M Brechbuhl,Remy Kachadourian,Elysia Min,Daniel Chan,Brian J Day.2011.Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: The role of glutathione. Toxicology and Applied Pharmacology (Impact Factor: 3.63), 258(1):1-9.
68. Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, Sultana S.2013.Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods, 23(5):337-45.
69. Kerr JF, Wyllie AH; Currie AR. Apoptosis: a basic biologic phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239–257.
70. Cohn JJ. Apoptosis. Immunology Today 1997, 14:120.
71. Hans Kristian Lorenzo, Santos A Susin, Josef Penninger and Guido Kroemer.1999. Apoptosis inducing factor (AIF): a phylogenetically old,caspase-independent effector of cell death.Cell death differentiation,6(6):516-524.
72. Santos A. Susin, Hans K. Lorenzo, Naoufal Zamzami, Isabel Marzo, Bryan E. Snow, Greg M. Brothers, Joan Mangion, Etienne Jacotot, Paola Costantini, Markus Loeffler, Nathanael Larochette, David R. Goodlett, Ruedi Aebersold, David P. Siderovski, Josef M. Penninger & Guido Kroeme.1998. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 397: 441-446.
73. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. The Company of Biologist, 2005 doi:10.1242/dev.01907.
74. Augustine Chen, Henry Beetham, Michael A Black, Rashmi Priya, Bryony J Telford, Joanne Guest,George A R Wiggins, Tanis D Godwin, Alpha S Yap and Parry J Guilford.2014. E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer , 2014, 14:552.
75. Siri Tveito,corresponding,Kristin Andersen, Rolf Kåresen, and Øystein Fodstad.2011.Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles. Breast Cancer Res,13(4): R75.